SCHEMBL3010530

SCHEMBL3010530

O=S(=O)(c1ccc(Br)cc1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.35
HTR2C P28335 2/20 0.35
KCNH2 Q12809 2/20 0.35
DRD2 P14416 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PROKR1 Q8TCW9 3/20 0.33
FPR2 P25090 2/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EPHX2 P34913 1/20 0.33
NAMPT P43490 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
DNM1L O00429 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
SCN1A P35498 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022500 0.93 HTR2A (0.37) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3017935 0.93 HTR2A (0.35) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3007239 0.93 HTR2A (0.40) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3011420 0.93 HTR2A (0.42) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3015207 0.92 SMN1; SMN2 (0.36) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3017508 0.92 LMNA (0.37) HTR2ASMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3016901 0.91 GBA1 (0.39) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3014833 0.91 L3MBTL1 (0.35) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3014287 0.91 RAB9A (0.33) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3004485 0.90 HTR2A (0.36) HTR2AHTR2CKCNH2DRD2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885HTR2C 1153/4885KCNH2 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.